https://www.fiercebiotech.com/biotech/immutep-takes-immunotherapy-step-further-impressive-survival-data-keytruda-combo
Immutep suggests that a high unmet need for first-line, PD-L1-negative HNSCC could potentially pave eftilagimod a path to approval.
immuteplagagentpostsimpressive